Clinical and basic research on steroid-induced osteonecrosis of the femoral head in Japan

Kubo, Toshikazu; Ueshima, Keiichiro; Saito, Motoki; Ishida, Masaharu; Arai, Yuji; Fujiwara, Hiroyoshi

doi:10.1016/j.jos.2016.03.008

Cited by 112 publications

(84 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is believed that long-term use of GCs can lead to hyperlipidemia and fat accumulation in the bone marrow cavity, which increases marrow cavity pressure and increases the risks of fat embolus formation, venous obstruction, and vascular endothelial damage, all of which promote avascular osteonecrosis. 17 Bian et al 18 reported that dexamethasone regulated lipid metabolism-associated microRNAs in osteogenically induced human mesenchymal stem cells. Metabolomics analysis performed on 30 patients with GC-induced ONFH and 30 healthy controls revealed that the abnormal metabolites induced by GCs were primarily in lipid-, glutathione-, nucleotide-, and energy-associated pathways.…”

Section: Hdl-c and Apo-b/apo-a1: Potential Predictive Value Of Lipid mentioning

confidence: 99%

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

Wang

Hua

Chang

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

Early diagnosis and prevention of glucocorticoid (GC)‐induced osteonecrosis of the femoral head (ONFH) continues to be a challenging problem for clinicians and researchers. However, the role of circulating biomarkers for GC‐induced ONFH, which may reveal individual susceptibility and facilitate earlier diagnosis, remains to be determined. The aim of this study was to identify potential biomarkers that may predict early GC‐induced ONFH. A total of 123 patients scheduled for initial systemic GC therapy were enrolled in this prospective nested case–control study. The serum concentrations of 13 potential biomarkers were measured in seven patients with GC‐induced ONFH, diagnosed instantly after short‐term use of GCs and in 20 controls who did not develop osteonecrosis despite similar GC therapy. Biomarkers were measured both before and after taking GCs to identify any differences in marker levels and the changes during GC therapy between two groups. Type I collagen cross‐linked C‐telopeptide (β‐CTX; p = 0.000) was significantly lower, high‐density lipoprotein cholesterol (p = 0.092) and apolipoprotein (apo)‐B/apo‐A1 (p = 0.085) tended to be lower and higher, respectively, before GC treatment in osteonecrosis group. After GC therapy, β‐CTX (p = 0.014) was significantly lower and amino terminal telopeptide of procollagen type I (PINP; p = 0.068) tended to be lower in the osteonecrosis group. As secondary outcomes, we observed remarkable changes in nine potential biomarkers following short‐term GC therapy in both groups. In conclusion, we found that β‐CTX, could potentially be used to predict GC‐induced ONFH before GC therapy. Lower β‐CTX and PINP are promising biomarkers for the early diagnosis of GC‐induced ONFH. These findings need to be confirmed in large‐scale prospective studies. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2348–2357, 2019

show abstract

Section: Hdl-c and Apo-b/apo-a1: Potential Predictive Value Of Lipid mentioning

confidence: 99%

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

Wang

Hua

Chang

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

show abstract

“…On the other hand, osteonecrosis of the jaw related with melphalan alone has not been reported, but it is known as a possible complication from corticosteroid therapy, either alone 10) or combined with other drugs 8) in the treatment of various diseases in humans. However, with regard to pharmacophysiology, it was unclear whether zoledronic acid administration contributed to mandibular necrosis in the current case.…”

Section: Case Descriptionmentioning

confidence: 99%

The Use of Zoledronic Acid for Solitary Osseous Plasmacytoma in a Dog

Zama

Befu

Namba³

et al. 2016

Japanese Journal of Veterinary Anesthesia & Surgery

View full text Add to dashboard Cite

Summary:A 12-year-old neutered male miniature dachshund was presented with intermittent ataxia. Solitary osseous plasmacytoma (SOP) in the 12th thoracic vertebra (T12) was diagnosed based on the results of diagnostic imaging and histopathology. The combination use of zoledronic acid, melphalan, and prednisolone was extremely effective and long term survival could be achieved, however, mandibular osteonecrosis developed as a suspected adverse effect of zoledronic acid 2 years later. This is the first clinical report of an adverse effect of zoledronic acid in a dog with SOP.

show abstract

“…The pathogenesis of ONFH in patients with inflammatory diseases treated with corticosteroids remains unclear, although there has reported as factors caused ischemia due to fat emboli in peripheral blood vessels, reduction in arterial flow through the recruitment of increased adipose tissue and/ or an increase in intramedullary pressure [4,5]. On the other hand, ONFH frequently results in osteoarthritis in young patients [6,7], and no effective prevention strategy or effective nonsurgical treatment for ONFH has been established to date.…”

Section: Introductionmentioning

confidence: 99%

The proton pump inhibitor, lansoprazole, prevents the development of non-traumatic osteonecrosis of the femoral head: an experimental and prospective clinical trial

Kosukegawa

Okazaki

Yamamoto

et al. 2020

Eur J Orthop Surg Traumatol

View full text Add to dashboard Cite

Background An effective prevention strategy for osteonecrosis of the femoral head (ONFH) has yet to be established. We previously reported that the innate immune system via the toll-like receptor (TLR) response induced by corticosteroids leads to the development of ONFH and that repression of IRF7 activity by an inhibitor could interfere with the development of ONFH while maintaining the therapeutic effect of the corticosteroids. Objective In the present study, we hypothesize that lansoprazole has the potential to suppress IRF7 activity and prevent corticosteroid-induced ONFH in rats. Furthermore, we conducted a preliminary clinical trial to prevent corticosteroid-induced ONFH in autoimmune disease patients. Methods Male Wistar rats were randomly divided into four groups. On Day 1, each rat was injected with TLR4 ligand (LPS) or TLR7 ligand (imiquimod), followed by methylprednisolone with or without lansoprazole on Day 2. They were killed at 1 or 14 days after the last injection.We prospectively recruited 30 patients requiring primary high-dose corticosteroid treatment for immune diseases. All patients were administered lansoprazole, starting the night before corticosteroid treatment began. MRI was performed before corticosteroid treatment, and at 4, 12 and 24 weeks afterward. Results In rats, co-treatment of lansoprazole with corticosteroids significantly repressed both IRF7 activity and the development of ONFH. Moreover, in the human patients, the incidence of ONFH was significantly decreased from 53.4 to 13.3%. Conclusions Although the present study is preliminary, the results show that co-treatment of lansoprazole with corticosteroids prevents ONFH development. Lansoprazole may be both safe and effective in preventing osteonecrosis of the femoral head in patients needing corticosteroid treatment.Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

Clinical and basic research on steroid-induced osteonecrosis of the femoral head in Japan

Cited by 112 publications

References 42 publications

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

The Use of Zoledronic Acid for Solitary Osseous Plasmacytoma in a Dog

The proton pump inhibitor, lansoprazole, prevents the development of non-traumatic osteonecrosis of the femoral head: an experimental and prospective clinical trial

Contact Info

Product

Resources

About